Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056271 · ClinicalTrials.gov registry record
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation
A clinical trial of Atrial Fibrillation, sponsored by Volta Medical.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT06056271: Recruiting study of Atrial Fibrillation, sponsored by Volta Medical.
NCT06056271 is a study of Atrial Fibrillation that is actively recruiting participants, run by Volta Medical. The registered enrollment target is 400 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06056271, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by Volta Medical.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.
Primary Outcome
Percentage of subjects free from clinically significant AF or atrial arrhythmia recurrences, after one or multiple ablation procedures, stratified by type of clinical workflow and ablation history.
Conditions Studied
Interventions
- DEVICE AF Ablation
Study Locations (4)
Illinois
- Endeavor Health - Evanston
Kansas
- Kansas City Cardiac Arrhythmia Research LLC - Overland Park
New York
- Northwell Health - New York
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2027-12 |
What NCT06056271 shows while recruiting
NCT06056271 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which AF Ablation is the first listed.
NCT06056271 reports a single indexed study location in Illinois, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT06056271 about?
NCT06056271 is a clinical study titled "Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation". Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.
What is the current status of trial NCT06056271?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-03-19. Estimated completion is 2027-12.
What conditions does trial NCT06056271 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT06056271?
The interventions under investigation include: AF Ablation (DEVICE).
Who is sponsoring clinical trial NCT06056271?
This trial is sponsored by Volta Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056271 being conducted?
This trial has 4 study locations across Illinois, Kansas, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06056271's enrollment target sits among peer trials
400 69th of 202 higher than 132 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI